AQST
Price
$5.84
Change
-$0.07 (-1.18%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
720.43M
111 days until earnings call
Intraday BUY SELL Signals
KNSA
Price
$42.13
Change
+$0.85 (+2.06%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
3.13B
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AQST vs KNSA

Header iconAQST vs KNSA Comparison
Open Charts AQST vs KNSABanner chart's image
Aquestive Therapeutics
Price$5.84
Change-$0.07 (-1.18%)
Volume$28.93K
Capitalization720.43M
Kiniksa Pharmaceuticals International
Price$42.13
Change+$0.85 (+2.06%)
Volume$7.06K
Capitalization3.13B
AQST vs KNSA Comparison Chart in %
AQST
Daily Signal:
Gain/Loss:
KNSA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AQST vs. KNSA commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a Hold and KNSA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (AQST: $5.91 vs. KNSA: $41.28)
Brand notoriety: AQST and KNSA are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AQST: 59% vs. KNSA: 89%
Market capitalization -- AQST: $711.28M vs. KNSA: $3.19B
AQST [@Pharmaceuticals: Generic] is valued at $711.28M. KNSA’s [@Pharmaceuticals: Generic] market capitalization is $3.19B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileKNSA’s FA Score has 1 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • KNSA’s FA Score: 1 green, 4 red.
According to our system of comparison, both AQST and KNSA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 4 TA indicator(s) are bullish while KNSA’s TA Score has 4 bullish TA indicator(s).

  • AQST’s TA Score: 4 bullish, 6 bearish.
  • KNSA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, KNSA is a better buy in the short-term than AQST.

Price Growth

AQST (@Pharmaceuticals: Generic) experienced а +3.78% price change this week, while KNSA (@Pharmaceuticals: Generic) price change was +1.75% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.77%. For the same industry, the average monthly price growth was -6.55%, and the average quarterly price growth was +28.28%.

Reported Earning Dates

AQST is expected to report earnings on Mar 10, 2026.

KNSA is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.77% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KNSA($3.13B) has a higher market cap than AQST($720M). KNSA YTD gains are higher at: 108.696 vs. AQST (65.871). KNSA has higher annual earnings (EBITDA): 39.6M vs. AQST (-47.5M). KNSA has more cash in the bank: 352M vs. AQST (60.5M). KNSA has less debt than AQST: KNSA (9.72M) vs AQST (40.3M). KNSA has higher revenues than AQST: KNSA (598M) vs AQST (44.1M).
AQSTKNSAAQST / KNSA
Capitalization720M3.13B23%
EBITDA-47.5M39.6M-120%
Gain YTD65.871108.69661%
P/E RatioN/A91.73-
Revenue44.1M598M7%
Total Cash60.5M352M17%
Total Debt40.3M9.72M415%
FUNDAMENTALS RATINGS
AQST vs KNSA: Fundamental Ratings
AQST
KNSA
OUTLOOK RATING
1..100
6311
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
9133
SMR RATING
1..100
10075
PRICE GROWTH RATING
1..100
3738
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5024

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AQST's Valuation (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for KNSA (76). This means that AQST’s stock grew somewhat faster than KNSA’s over the last 12 months.

KNSA's Profit vs Risk Rating (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for AQST (91). This means that KNSA’s stock grew somewhat faster than AQST’s over the last 12 months.

KNSA's SMR Rating (75) in the Pharmaceuticals Major industry is in the same range as AQST (100). This means that KNSA’s stock grew similarly to AQST’s over the last 12 months.

AQST's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as KNSA (38). This means that AQST’s stock grew similarly to KNSA’s over the last 12 months.

AQST's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as KNSA (100). This means that AQST’s stock grew similarly to KNSA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTKNSA
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 13 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
AQST
Daily Signal:
Gain/Loss:
KNSA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DCDGX12.29N/A
N/A
Dunham Small Cap Growth C
AULDX112.85N/A
N/A
American Century Ultra® R6
ABIZX22.66N/A
N/A
AMG River Road Mid Cap Value Z
TRLUX24.41-0.08
-0.33%
T. Rowe Price Lrg Cp Va Inv
IRLIX44.74-0.43
-0.95%
Voya Russell Large Cap Index Port A

AQST and

Correlation & Price change

A.I.dvisor tells us that AQST and NBIX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AQST and NBIX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
+1.46%
NBIX - AQST
30%
Poorly correlated
-3.44%
ETON - AQST
29%
Poorly correlated
-0.41%
TLRY - AQST
28%
Poorly correlated
-0.49%
ESPR - AQST
27%
Poorly correlated
+0.35%
KNSA - AQST
27%
Poorly correlated
-0.29%
More

KNSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with COYA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then COYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNSA
1D Price
Change %
KNSA100%
-0.29%
COYA - KNSA
42%
Loosely correlated
+4.38%
ABVC - KNSA
40%
Loosely correlated
+1.38%
JBIO - KNSA
37%
Loosely correlated
+0.52%
AMRN - KNSA
36%
Loosely correlated
+4.33%
CPRX - KNSA
36%
Loosely correlated
+0.44%
More